Skip to main content

Depression Not Likely to Cause Cognitive Impairment


A new study suggests that depression often accompanies cognitive impairment but does not precede it.
"Traditionally, cognitive complaints and impairment in the presence of depression has been considered to be caused by the depression. Our study suggests that depression is not a cause of dementia but accompanies the onset of cognitive impairment," José Alejandro Luchsinger, MD, MPH, associate professor of medicine and epidemiology, Columbia University Medical Center, New York City, told Medscape Medical News.
The study was published online December 31, 2012 in Archives of Neurology.
Transition Time Crucial Period
Patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) often have depressive symptoms, but the mechanisms underlying the association remain unclear.
"Depression could be a risk factor for dementia, an early dementia symptom, a reaction to cognitive and functional disability, or a symptom of a related risk factor, such as cerebrovascular disease," Dr. Luchsinger and colleagues point out. "Vascular factors have been linked to late-life depression, and cerebrovascular disease might be an important contributor to MCI…. However, there is a paucity of data examining the association between depression and MCI."
Dr. José Alejandro Luchsinger
The researchers evaluated the association of late-life depression with MCI and dementia in a multiethnic group of 2160 community-dwelling Medicare recipients.
They report that depression at baseline was associated with prevalent MCI (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.1 - 1.9) and prevalent dementia (OR, 2.2; 95% CI, 1.6 - 3.1).
Baseline depression was also associated with an increased risk for incident dementia (hazard ratio [HR], 1.7; 95% CI, 1.2 - 2.3) but not with incident MCI (HR, 0.9; 95% CI, 0.7 - 1.2).
In addition, individuals with MCI and coexisting depression at baseline had a higher risk for progression to dementia (HR, 2.0; 95% CI, 1.2 - 3.4), especially vascular dementia (HR, 4.3; 95% CI, 1.1 - 17.0), but not AD (HR, 1.9; 95% CI, 1.0 - 3.6).
"Our finding that depression was associated cross sectionally with both MCI and dementia and longitudinally only with dementia suggests that depression develops with the transition from normal cognition to dementia," the authors conclude.
Dr. Luchsinger said, "Clinicians should consider the possibility that depression and cognitive impairment could be the joint manifestation of a cognitive disorder, particularly in elderly persons. Our research did not directly address this, and more research is needed to understand if the depression is part of the cognitive process or a reaction to it."
Mechanisms?
"There has now been an accumulation of enough studies and enough data to say that people with a history of depression do have increased rates of cognitive decline and dementia in late life," Meryl Butters, PhD, neuropsychologist and associate professor of psychiatry, University of Pittsburgh School of Medicine, Pennsylvania, who was not involved in the study, noted in an interview with Medscape Medical News.
"The issue now really is, what are the mechanisms? What is it about a mood disorder earlier in life that might place you at risk for progressive dementia in late life? This study can't address that," she said.
Dr. Butters said "a handful" of researchers, including herself, are now looking at possible mechanisms behind depression and cognitive decline. "This is a very active area of investigation. It's likely that different mechanisms are at work in different people."
The authors have disclosed no relevant financial relationships.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more